(Q38267346)

1 September 2017

1 reference

title

Dapagliflozin: a review of its use in patients with type 2 diabetes (English)

1 reference

1 September 2017

1 reference

1

Greg L Plosker

1 reference

1 September 2017

publication date

1 December 2014

1 reference

1 September 2017

1 reference

1 September 2017

volume

74

1 reference

1 September 2017

issue

18

1 reference

1 September 2017

page(s)

2191-2209

1 reference

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

1 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0324-3

Diagnosis and Classification of Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0324-3

Standards of medical care in diabetes--2014

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0324-3

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0324-3

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0324-3

Dapagliflozin: a review of its use in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0324-3

Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0324-3

Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0324-3

Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0324-3

Renal effects of dapagliflozin in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0324-3

Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0324-3

Towards better understanding of the contributions of overwork and glucotoxicity to the beta-cell inadequacy of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0324-3

Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0324-3

Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0324-3

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0324-3

In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0324-3

Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0324-3

Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0324-3

Drug-drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0324-3

Impact of voglibose on the pharmacokinetics of dapagliflozin in Japanese patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0324-3

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0324-3

Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0324-3

Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0324-3

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0324-3

Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0324-3

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0324-3

Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0324-3

Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0324-3

Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: a randomized, double-blind, parallel-group, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0324-3

Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0324-3

Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0324-3

Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0324-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0324-3

Changes in weight loss-related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0324-3

A systematic review and mixed-treatment comparison of dapagliflozin with existing anti-diabetes treatments for those with type 2 diabetes mellitus inadequately controlled by sulfonylurea monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0324-3

Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0324-3

Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0324-3

Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0324-3

Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0324-3

Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0324-3

Dapagliflozin as monotherapy or combination therapy in Japanese patients with type 2 diabetes: an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0324-3

Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0324-3

Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0324-3

Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0324-3

Urinary tract infections in patients with diabetes treated with dapagliflozin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0324-3

Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0324-3

Carcinogenicity risk assessment supports the chronic safety of dapagliflozin, an inhibitor of sodium-glucose co-transporter 2, in the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0324-3

Impact of sodium glucose cotransporter 2 inhibitors on weight in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0324-3

Canagliflozin: a review of its use in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0324-3

Cost effectiveness of adding dapagliflozin to insulin for the treatment of type 2 diabetes mellitus in the Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0324-3

Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes

21 January 2018

1 reference

12 December 2020

Simultaneous oral therapeutic and intravenous ¹⁴C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin

1 reference

12 December 2020

Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension

1 reference

12 December 2020

Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial

1 reference

12 December 2020

Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin

1 reference

12 December 2020

Effect of a high-fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2 inhibitor, in healthy subjects

1 reference

12 December 2020

Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study.

1 reference

12 December 2020

The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-analysis of randomised controlled trials

1 reference

12 December 2020

Pharmacokinetic and pharmacodynamic properties of single- and multiple-dose of dapagliflozin, a selective inhibitor of SGLT2, in healthy Chinese subjects

1 reference

12 December 2020

Cost-effectiveness of dapagliflozin (Forxiga®) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries

1 reference

12 December 2020

Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin

1 reference

12 December 2020

10.1007/S40265-014-0324-3

Identifiers

DOI

1 reference

Dimensions Publication ID

1 September 2017

1008919395

0 references

1 reference